Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Mingxiang Liao"'
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 47:711-723
Lucitanib is an oral, potent, selective inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1‒3, fibroblast growth factor receptors 1‒3, and platelet-derived growth factor receptors alpha/beta.We aimed to dev
Autor:
Liliane, Robillard, Mingxiang, Liao, Minh, Nguyen, Thomas C, Harding, Andrew D, Simmons, Rachel L, Dusek
Publikováno v:
Journal of Immunotherapy. 45:335-348
Lucitanib is a multi-tyrosine kinase inhibitor whose targets are associated with angiogenesis and other key cancer and immune pathways. Its antiangiogenic properties are understood, but lucitanib's immunomodulatory activity is heretofore unknown. Luc
Publikováno v:
2022 China Automation Congress (CAC).
Publikováno v:
2022 41st Chinese Control Conference (CCC).
Autor:
Mingxiang Liao, Jeri Beltman, Heidi Giordano, Thomas C. Harding, Lara Maloney, Andrew D. Simmons, Jim J. Xiao
Publikováno v:
Clinical pharmacokinetics. 61(11)
Rucaparib is an oral small-molecule poly(ADP-ribose) polymerase inhibitor indicated for patients with recurrent ovarian cancer in the maintenance and treatment settings and for patients with metastatic castration-resistant prostate cancer associated
Publikováno v:
Xenobiotica. 50:1032-1042
1. The absorption, distribution, metabolism, elimination, and drug-drug interaction (DDI) potential of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib was characterised in vitro.2. Rucap...
Autor:
Mingxiang Liao, Fang Wan, Yuan Yao, Zhenjun Han, Jialing Zou, Yuze Wang, Bailan Feng, Peng Yuan, Qixiang Ye
Publikováno v:
Lecture Notes in Computer Science ISBN: 9783031200762
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a01dd586f7c470692cc12f82e349cc8c
https://doi.org/10.1007/978-3-031-20077-9_13
https://doi.org/10.1007/978-3-031-20077-9_13
Autor:
Eileen Nash, Jeff Etter, Abdul Mutlib, Li Shen, Jeff Isaacson, Jim J. Xiao, Jeri Beltman, Pascal van Tilburg, Mingxiang Liao, Rong Fan, Vendel Kemeny, Simon Paul Watkins, Zsuzsanna Papai
Publikováno v:
Investigational New Drugs
Summary Rucaparib, a poly(ADP-ribose) polymerase inhibitor, is licensed for use in recurrent ovarian, fallopian tube, or primary peritoneal cancer. We characterized the absorption, distribution, metabolism, and elimination of rucaparib in 6 patients
Autor:
Mingxiang, Liao, Sarah, Jaw-Tsai, Jeri, Beltman, Andrew D, Simmons, Thomas C, Harding, Jim J, Xiao
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 50(9)
1. The absorption, distribution, metabolism, elimination, and drug-drug interaction (DDI) potential of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib was characterised
Autor:
Emily Guan, Christopher Gemski, Andy Z. X. Zhu, Bingli Ma, Mingxiang Liao, Albert P. Li, Cindy Q. Xia, Guangqing Xiao, Qing Zhu
Publikováno v:
Xenobiotica. 49:852-862
A thorough understanding of species-dependent differences in hepatic uptake transporters is critical for predicting human pharmacokinetics (PKs) from preclinical data. In this study, the activities of organic anion transporting polypeptide (OATP/Oatp